Merck announced on Thursday that its blockbuster cancer drug Keytruda missed the primary endpoint in a phase III study. Investigators were testing the checkpoint inhibitor as a potential second-line treatment for patients diagnosed with advanced gastric or gastroesophageal junction adenocarcinoma whose disease progressed after first-line treatment with platinum and fluoropyrimidine doublet therapy. Results from the…
First Human Trial for New Huntington’s Disease Drug Shows Promise
Novel Compound Could Produce New Autoimmune Therapies
EMA HQ Heads to Amsterdam
Two FDA Approvals Boost Roche Blood Disease Portfolio
Valeant to Sell ‘Female Viagra’ to Former Owners
Valeant Pharmaceuticals announced plans to sell off a controversial acquisition. The company will sell Sprout Pharmaceuticals, the firm that developed Addyi which is a little pink pill labeled as the “female Viagra” to a buyer affiliated with former shareholders of Sprout. This decision comes on the heels of buying the company two years ago for…
Two Firms Make Big Bets on Alzheimer’s R&D
More Evidence Ketamine Could Alleviate Migraine Pain
New Clinical Deal Will Test Novel Peanut Allergy Drug
How Biomarkers Could Help Inform Early Stage Clinical Trial Design
New Collaboration Designed to Advance Cancer Drug R&D
‘Smart Bandage’ Could Accelerate Healing of Chronic Injuries and Battlefield Wounds
Quantum Dots Could Supercharge Antibiotic Treatments
Axovant Sciences Announces Alzheimer’s Drug Flop
Alnylam Achieves Major Breakthrough with RNAi Drug
Study Suggests Route to Single Vaccine for Multiple Viruses
Alexion Pharmaceuticals Plans More Job Cuts
AstraZeneca Reveals Promising PFS Data for Lung Cancer Drug
Erytech Unveils New Data for Pancreatic Cancer Combination Therapy
Experimental Cell Therapy Shows Promise for Parkinson’s
A potential approach to treating Parkinson’s disease has emerged in an animal study. Researchers from Kyoto University reported promising results from a trial that entailed implanting induced pluripotent (iPS) stem cells into the brains of monkeys who had a version of the neurodegenerative disorder caused by a neuron-killing toxin. Pluripotent stem cells have the ability…
Eli Lilly Initiates Global Restructuring
Nanoparticle Advance Could Yield Multi-Purpose Treatments
Xarelto Aspirin Regimen Lowers CV Event Risk in Phase III Study
Antibiotic ‘Superteam’ Could Quash Invincible Superbug
A trio of antibiotics could hold the key to eradicating a deadly superbug for good. Researchers at the University of Buffalo discovered a novel combination of aztreonam, amikacin, and polymyxin B – a last resort antibiotic — was able to simultaneously kill E. coli bacterium strains carrying mcr-1 and ndm-5 genes within 24 hours while…